The efficiency of extracts of plants that have

449 views

Published on

Published in: Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
449
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
13
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The efficiency of extracts of plants that have

  1. 1. EFFICIENCY OF PLANTS EXTRACTS THAT CONTAIN MELATONIN IN PARKINSON DISEASE RATS Carlos J. Santos Pérez, RISE Student
  2. 2. Background Information  The rats have a very similar neurological system to human.  The cause of Parkinson Disease in a patient is the absence of dopamine.  Symptoms:  Trembling of the extremities  Stiffness  Slowness  Poor balance or coordination
  3. 3. Melatonin  Is an hormone that is produce in the brain by the pineal gland, from the amino acid tryptophan.  Synthesis and release of melatonin are stimulated by darkness and suppressed by light, suggesting the involvement of melatonin in circadian rhythm and regulation of diverse body functions.  Levels of melatonin in the blood are highest prior to bedtime.
  4. 4. Melatonin Extract: Achillea millefolium  Achillea millefolium- a plant that is commonly called Achillea, we can found it in North America and it contains a high concentration of melatonin  45.4 ng/g of the plant.
  5. 5. Melatonin & Alzheimer  Recent studies indicate that the presence of melatonin in Alzheimer improve patient health, so we can investigate if melatonin has the same effect in patients with other neurodegenerative disease , in this case Parkinson’s Disease.
  6. 6. Objectives  The objectives of this investigation are:  Determine if the extract of Achillea help patience with Parkinson Disease to control their involuntarily movements.  Prove that melatonin is a diverse remedial hormone that can be use to treat Parkinson Disease Symptoms including the lack of sleeping symptom
  7. 7. Hypothesis  If we apply melatonin extract of Achillea plant in rats with Parkinson Disease then we should see less involuntarily movement in the rats at higher concentrations of extract.
  8. 8. Rotenone  The Rotenone Molecule is a mithocondrial inhibitor that have been used to induce dopaminergic neuronal death.  Inhibit the pathway of dopamine production.  That’s why it cause Parkinson’s Disease.  Rotenone at 3 mg/kg/day will induce degeneration of the nigrostriatal dopaminergic pathway (Caboni, 2004)  This will be subcutaneously
  9. 9. Procedure  Extracts of Achillea millefolium.  Need a Population of mice for the experiment.  Groups:  Control- It consist of 25 healthy rats and 25 sick rats. They will not be affected by the extracts of Achillea millefolium.  Experimental- It consist of three group:  Concentration of 60%, will be injected subcutaneously.(25 rats)  Concentration of 10% , will be injected subcutaneously(25 rats)
  10. 10. Rats Control Group Experimental Group Rats with Rats with Parkinson’s- 40% Rats with Parkinson’s Healthy Rat(No Parkinon’s concentration of 10% of ML(5mL ML) Disease(No Ml) ML(5mL subcutaneously) subcutaneously) Alcohol(25) Levodopa(25)
  11. 11. How to do the extracts?  Tincture- Alcoholic extract that alcohol is the solvent.  We will use: 40% and 90% of alcohol and plant.  The ethanol extract have to be placed in rotatory evaporator to eliminate the solvent, obtaining an extract, which was weighed and stored in dissecator.
  12. 12. Variables  Time of Dosis of both of the concentrations: daily 5ml/day This will be for at least 1 year.  Independent Variables- Concentrations and dosis of the extracts may vary.  Dependent Variable- the temblors and involuntary movements of the rats.  Type of Data- Qualitative. This research is based on the observation of the rats behaviors.
  13. 13. Goals  If my hypothesis is reaffirmed I will proceed to use different plants to do the extracts and compare results.  As a second phase for my research project I will expand my research work to primates.
  14. 14. References  Ferri, Fred F. Practical guide to the care of the medical patient. – 7th ed. Pages: 776-777  Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol. 1994;Page 17  Marioni F. A straightforward procedure to biosynthesise melatonin using freshly chopped Achillea millefolium L. as reagent Phytochemistry Letters, Volume 1, Issue 2, 21 August 2008, Pages 107-110  German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol. 1989; 26:507–514.  http://www.ncbi.nlm.nih.gov/pubmed/18289173 Last visit- 7/25/2010  http://www.ncbi.nlm.nih.gov/pubmed/18289173 Last visit- 7/25/2010  http://www.ncbi.nlm.nih.gov/pubmed/15540952 Last visit- 7/25/2010  http://www.ncbi.nlm.nih.gov/pubmed/15540952 Last visit- 7/25/2010

×